EMA Authorised: Kayshild (semaglutide) — Novo Nordisk A/S

View source ↗

Summary

EU medicines regulator authorised Kayshild (semaglutide) by Novo Nordisk A/S for non-alcoholic fatty liver disease and liver cirrhosis, with conditional approva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cirrhosis
• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Kayshild (semaglutide)

Snippet

Status: Authorised. Therapeutic area: Non-alcoholic Fatty Liver Disease;Liver Cirrhosis. MAH: Novo Nordisk A/S. Decision date: 26/03/2026. Conditional approval